Temporary Arterial Balloon Occlusion as an Adjunct to Yttrium-90 Radioembolization
Temporary Arterial Balloon Occlusion as an Adjunct to Yttrium-90 Radioembolization
复制标题
DOI：
10.1007/s00270-012-0523-9
复制
发表时间：
2013-06-01
影响因子：
2.9
通讯作者：
Bozlar, Ugur
中科院分区：
文献类型：
--
作者：
Hagspiel, Klaus D.;Nambiar, Ashwin;Bozlar, Ugur
这项研究旨在描述在Yttrium-90放射栓塞术中使用临时闭塞球囊系统替代线圈闭塞肝肿瘤的动脉闭塞技术。回顾了连续接受肿瘤栓塞术的患者的图表、血管造影术和随访影像研究，其中使用HyperForm系统(ev3 Neuroventor，Irvine，CA)。记录术中靶血管闭塞情况和随访时靶血管的通畅率。回顾临床资料和韧致辐射扫描以寻找非靶点栓塞术的证据。3名患者(均为女性，年龄48-54岁，平均52岁)进行了4次放射栓塞术。5条动脉暂时闭塞(3条胃十二指肠动脉，1条胃右动脉，1条胆囊动脉)。所有放射栓塞术均顺利完成。所有患者在术后28-454天(平均183天)进行随访(数字减影血管造影术(DSA)或计算机断层血管造影术(CTA))，显示所有5条血管均通畅。未发现非靶点栓塞术的临床或影像证据。放射栓塞术中对中小动脉的暂时性球囊闭塞可以在早期和中期的随访中安全地治疗并保留术后血管的通畅。
This study was designed to describe the technique of arterial occlusion using a temporary occlusion balloon system as an alternative to coil occlusion during Yttrium-90 radioembolization of hepatic tumors.Review of charts, angiography, and follow-up imaging studies of consecutive patients undergoing oncological embolization procedures in which a HyperForm system (ev3 Neurovascular, Irvine, CA) was used. Intraprocedural target vessel occlusion and patency of the target vessel on follow-up were recorded. Clinical data and Bremsstrahlung scans were reviewed for evidence of nontarget embolization.Four radioembolization procedures were performed in three patients (all female, age 48-54 (mean 52) years). Five arteries were temporarily occluded (three gastroduodenal arteries, one right gastric artery, and one cystic artery). All radioembolization procedures were successfully completed. Follow-up imaging (either digital subtraction angiography (DSA) or computed tomography angiography (CTA)) was available for all patients between 28-454 (mean 183) days following the procedure, demonstrating all five vessels to be patent. No clinical or imaging evidence for nontarget embolization was found.Temporary balloon occlusion of small and medium-sized arteries during radioembolization allows safe therapy with preserved postprocedural vessel patency on early and midterm follow-up.